Evaluation of a new automated third-generation anti-HCV enzyme immunoassay
✍ Scribed by D. Lavanchy; J. Steinmann; A. Möritz; P. C. Frei
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 506 KB
- Volume
- 10
- Category
- Article
- ISSN
- 0887-8013
No coin nor oath required. For personal study only.
✦ Synopsis
The new Cobas Core Anti-HCV EIA was evaluated in two centers for its ability to detect antibodies directed to hepatitis C virus in human serum. This assay, which can be run fully automated on a random access analyzer, was compared with three other commercially available screening tests: the Ortho HCV 3.0 ELISA, the Murex anti-HCV, and theAbbotl HCV EIAsecond generation. Posi- tive or discrepant results were further investigated using the Wellcozyme HCV Western Blot or the Abbott Matrix HCV assays.
The results obtained from analyzing 5045 serum samples showed a high correlation between the Cobas CoreAnti-HCV ElAand the other screening assays, ranging from 98.9% to 99.9%. Diagnostic specificities and sensitivities ranged from 99.7% to 100% and from 98.8% to loo%, respectively. In this study, the Cobas Core Anti-HCV EIA proved to be a very convenient test, able to perform at the highest levels of sensitivity and specificity. o 1996 Wiley-Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract High throughput assays for anti‐SARS‐CoV IgG antibody detection are need for large‐scale epidemiologic studies. The performance of a microplate enzyme immunoassay, DETECT‐SARS™, was evaluated for the detection of anti‐SARS‐CoV IgG antibody. This assay is based on synthetic peptides deri
## Abstract ELISA methods to detect anti‐double‐stranded DNA (anti‐dsDNA) antibodies are highly sensitive, but are less specific for the diagnosis of SLE than the immunofluorescence test on Crithidia luciliae (CLIFT) and the Farr assay because they also detect low‐avidity antibodies. This study eva